Here’s why the GSK share price jumped 8% today

Edward Sheldon looks at why GlaxoSmithKline plc’s (LON: GSK) share price is up significantly today.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Looking at the FTSE 100 today, healthcare giant GlaxoSmithKline (LSE: GSK) is clearly the top performer. Its shares are up 7.6% as I write, versus a rise of 0.9% for the index. According to Thomson Reuters, this is the single largest gain in the price in nine years. So what’s the driver of the price surge?

Consumer healthcare joint venture

The reason GSK shares are flying today is that the company has announced that it has reached an agreement with Pfizer to combine their consumer health businesses into a new ‘world-leading’ joint venture that will have combined sales of nearly £10bn. Glaxo will have a majority controlling equity interest of 68%, while Pfizer will have the remaining 32%.

The combination will bring together two highly-complementary portfolios of trusted consumer health brands, including GSK’s Sensodyne, Voltaren and Panadol, and Pfizer’s Advil, Centrum and Caltrate, the the JV to be the global leader in over-the-counter (OTC) products via a market share of 7.3%, according to the company.

GSK believes that the operation will be well positioned to deliver stronger sales, cash flow, and earnings growth and generate substantial cost synergies, and has said that it expects the proposed transaction to be accretive to adjusted earnings and free cash flow in the first full year after closing.

Demerger

Furthermore, given that the proposed transaction is “transformational” to the scale of its Consumer Healthcare business, Glaxo has advised that it plans to separate the JV via a demerger, and list GSK Consumer Healthcare on the stock market separately within three years of closing the transaction. “Ultimately, our goal is to create two exceptional, UK-based global companies, with appropriate capital structures, that are each well positioned to deliver improving returns to shareholders and significant benefits to patients and consumers,” said CEO Emma Walmsley.

Dividend

In other important news this morning, GSK said that it remains committed to its current dividend policy and that it expects to pay dividends of 80p per share both this year and next. The company also stated that it believes it will be well placed to deliver returns to shareholders, as well as invest in its strategic priorities going forward.

Thoughts on the deal

My thoughts on this news? I think the deal is a positive development. The joint venture means that GSK will become the OTC market leader in categories such as pain relief, digestive health, and therapeutic oral health across almost all major geographies in the world, and this should help generate significant cost savings that can be reinvested in the business.

The demerger should also create a business that is capable of generating relatively stable revenues and cash flows, which is another plus. Jefferies analyst Peter Welford points out that the consumer healthcare division could potentially support higher debt levels and as a result, this could ‘deleverage’ the pharma and vaccines business. 

As a dividend investor, I also like the news that the dividend will be maintained this year and next. At the current share price, the stock supports a yield of 5.2%.

Are the shares a ‘buy’ right now? With analysts expecting GSK to generate earnings per share of 114p for FY2018, the shares currently trade on a P/E ratio of 13.5. I think that’s a reasonable price to pay for a slice of the business.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 industry-leading value stocks investors should consider buying

These value stocks are at the top of their respective industries, and look like current bargains with the potential to…

Read more »

Black father and two young daughters dancing at home
Investing Articles

Just released: our 3 top small-cap stocks to buy before August [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

If I’d put £5k in a FTSE 100 index fund 10 years ago, here’s what I’d have now!

Charlie Carman explores the performance of the FTSE 100 index over the past decade and the merits of passive versus…

Read more »

Investing Articles

£15K stashed away? I could turn that into a second income worth £49 a day!

This Fool explains how she would look to gain a second income through investing in UK stocks, and the steps…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

With the Apple share price near an all-time high, would I be crazy to buy more?

After touching all-time highs yesterday, the Apple share price is on a roll. But is there still enough growth ahead…

Read more »

Investing Articles

Nvidia stock has fallen 13% from its 52-week high! What next?

Our writer explains why Nvidia stock has dipped recently and highlights some risks associated with investing in the AI leader…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

The AstraZeneca share price is up 88% in 5 years, but is it just getting started?

The AstraZeneca share price has had a great few years, as acquisitions and clinical trials delighted shareholders. So is there…

Read more »

Investing Articles

Here’s why I’m watching the Anglo American share price

The mining sector has always interested investors. But after a flat few years, I'm wondering what's next for the Anglo…

Read more »